FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312052409> ?p ?o ?g. }

• W4312052409 endingPage "L19" @default.
• W4312052409 startingPage "L10" @default.
• W4312052409 abstract "Abstract The syndrome of heart failure (HF) has historically been dichotomized based on clinical trial inclusion criteria into patients with a reduced or preserved left ventricular ejection fraction (LVEF) using a cut-off of above or below 40%. The majority of trial evidence for the benefits of disease-modifying pharmacological therapy has been in patients with HF with reduced ejection fraction (HFrEF), i.e. those with an LVEF ≤40%. Recently, the sodium-glucose co-transporter 2 inhibitors empagliflozin and dapagliflozin have been shown to be the first drugs to improve outcomes in HF across the full spectrum of LVEF. There is, however, growing evidence that the benefits of many of the neurohumoral modulators shown to be beneficial in patients with HFrEF may extend to those with a higher LVEF above 40% but still below the normal range, i.e. HF with mildly reduced ejection fraction (HFmrEF). Whether the benefits of some of these medications also extend to patients with HF and preserved ejection fraction (HFpEF) is an area of ongoing debate. This article will review the evidence for HF treatments across the full spectrum of LVEF, provide an overview of recently updated clinical practice guidelines, and address the question whether it may now be time to treat HF with some therapies regardless of ejection fraction." @default.
• W4312052409 created "2023-01-04" @default.
• W4312052409 creator A5007964446 @default.
• W4312052409 creator A5016593285 @default.
• W4312052409 creator A5051264655 @default.
• W4312052409 creator A5055212510 @default.
• W4312052409 creator A5067422552 @default.
• W4312052409 creator A5078764628 @default.
• W4312052409 creator A5079420772 @default.
• W4312052409 date "2022-12-19" @default.
• W4312052409 modified "2023-10-14" @default.
• W4312052409 title "The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?" @default.
• W4312052409 cites W1518281645 @default.
• W4312052409 cites W1811184201 @default.
• W4312052409 cites W1870916828 @default.
• W4312052409 cites W1989500574 @default.
• W4312052409 cites W2028139057 @default.
• W4312052409 cites W2068519950 @default.
• W4312052409 cites W2076595931 @default.
• W4312052409 cites W2098780362 @default.
• W4312052409 cites W2104209472 @default.
• W4312052409 cites W2113698123 @default.
• W4312052409 cites W2119061468 @default.
• W4312052409 cites W2119369020 @default.
• W4312052409 cites W2124624517 @default.
• W4312052409 cites W2127254785 @default.
• W4312052409 cites W2152072062 @default.
• W4312052409 cites W2152094259 @default.
• W4312052409 cites W2154650976 @default.
• W4312052409 cites W2163584170 @default.
• W4312052409 cites W2164705414 @default.
• W4312052409 cites W2166736523 @default.
• W4312052409 cites W2167760816 @default.
• W4312052409 cites W2187526770 @default.
• W4312052409 cites W2187887962 @default.
• W4312052409 cites W2218786242 @default.
• W4312052409 cites W2296998040 @default.
• W4312052409 cites W2323458614 @default.
• W4312052409 cites W2326508838 @default.
• W4312052409 cites W2330699098 @default.
• W4312052409 cites W2340731691 @default.
• W4312052409 cites W2475261460 @default.
• W4312052409 cites W2585382523 @default.
• W4312052409 cites W2609231773 @default.
• W4312052409 cites W2612219720 @default.
• W4312052409 cites W2761111693 @default.
• W4312052409 cites W2790275265 @default.
• W4312052409 cites W2886546649 @default.
• W4312052409 cites W2888036721 @default.
• W4312052409 cites W2966052071 @default.
• W4312052409 cites W2971294569 @default.
• W4312052409 cites W2974260792 @default.
• W4312052409 cites W2987185485 @default.
• W4312052409 cites W2989425857 @default.
• W4312052409 cites W3009245752 @default.
• W4312052409 cites W3013393618 @default.
• W4312052409 cites W3021063182 @default.
• W4312052409 cites W3023522280 @default.
• W4312052409 cites W3035255089 @default.
• W4312052409 cites W3081778241 @default.
• W4312052409 cites W3081830235 @default.
• W4312052409 cites W3082758064 @default.
• W4312052409 cites W3092379111 @default.
• W4312052409 cites W3092434593 @default.
• W4312052409 cites W3096702313 @default.
• W4312052409 cites W3100542962 @default.
• W4312052409 cites W3115836333 @default.
• W4312052409 cites W3132494856 @default.
• W4312052409 cites W3133956714 @default.
• W4312052409 cites W3149508638 @default.
• W4312052409 cites W3158049170 @default.
• W4312052409 cites W3173564302 @default.
• W4312052409 cites W3193293922 @default.
• W4312052409 cites W3193297191 @default.
• W4312052409 cites W3193316662 @default.
• W4312052409 cites W3193598686 @default.
• W4312052409 cites W3193680471 @default.
• W4312052409 cites W3197041435 @default.
• W4312052409 cites W3212078462 @default.
• W4312052409 cites W4200116290 @default.
• W4312052409 cites W4200236165 @default.
• W4312052409 cites W4200586754 @default.
• W4312052409 cites W4205124682 @default.
• W4312052409 cites W4225408423 @default.
• W4312052409 cites W4229333036 @default.
• W4312052409 cites W4245244523 @default.
• W4312052409 cites W4293332098 @default.
• W4312052409 cites W4293353625 @default.
• W4312052409 cites W4293354639 @default.
• W4312052409 cites W52877415 @default.
• W4312052409 doi "https://doi.org/10.1093/eurheartjsupp/suac113" @default.
• W4312052409 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36545228" @default.
• W4312052409 hasPublicationYear "2022" @default.
• W4312052409 type Work @default.
• W4312052409 citedByCount "6" @default.
• W4312052409 countsByYear W43120524092023 @default.
• W4312052409 crossrefType "journal-article" @default.
• W4312052409 hasAuthorship W4312052409A5007964446 @default.

• next